1. Soligenix, Inc. (Nasdaq: SNGX) CEO Christopher Schaber - Interview - RICH TV LIVE

    Soligenix, Inc. (Nasdaq: SNGX) CEO Christopher Schaber - Interview - RICH TV LIVE

    15
    2
    61
  2. Revolutionizing Rare Disease Treatment: Introducing Soligenix's Breakthrough HyBryte™

    Revolutionizing Rare Disease Treatment: Introducing Soligenix's Breakthrough HyBryte™

    12
  3. HyBryte™ by Soligenix: Transforming Cutaneous T-Cell Lymphoma Treatment

    HyBryte™ by Soligenix: Transforming Cutaneous T-Cell Lymphoma Treatment

    17
  4. Soligenix: Late-Stage Biopharma Addressing a $2 Billion Opportunity

    Soligenix: Late-Stage Biopharma Addressing a $2 Billion Opportunity

    3
  5. Soligenix: Advancing Rare Disease Treatments and Fighting Emerging Diseases

    Soligenix: Advancing Rare Disease Treatments and Fighting Emerging Diseases

    3
    0
    6
  6. September 2023 - Learn How This Company Is Rising to the Challenge of Rare Disease Treatment of Cutaneous T-Cell Lymphoma and Psoriasis

    September 2023 - Learn How This Company Is Rising to the Challenge of Rare Disease Treatment of Cutaneous T-Cell Lymphoma and Psoriasis

    23
  7. May 2023 - Learn How This Company Is Rising to the Challenge of Rare Disease Treatment for Lymphoma and Psoriasis

    May 2023 - Learn How This Company Is Rising to the Challenge of Rare Disease Treatment for Lymphoma and Psoriasis

    11
  8. Soligenix: Illuminating the Future of Rare Disease Therapies

    Soligenix: Illuminating the Future of Rare Disease Therapies

    6